2023
Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health
STUHEC, Matej, M. HAHN, Ivana TAŠKOVÁ, I. BAYRAKTAR, I. FITZGERALD et. al.Základní údaje
Originální název
Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health
Autoři
STUHEC, Matej (705 Slovinsko), M. HAHN (276 Německo), Ivana TAŠKOVÁ (203 Česká republika, domácí), I. BAYRAKTAR (792 Turecko), I. FITZGERALD (372 Irsko), L. MOLITSCHNIG (40 Rakousko), A. TATAREVIC (191 Chorvatsko), N. LINDNER (40 Rakousko), L. AGNOLETTO (40 Rakousko) a F. DA COSTA (620 Portugalsko)
Vydání
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, NETHERLANDS, SPRINGER, 2023, 2210-7703
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.400 v roce 2022
Kód RIV
RIV/00216224:14160/23:00133605
Organizační jednotka
Farmaceutická fakulta
UT WoS
001073897200001
Klíčová slova anglicky
Clinical pharmacist interventions; Clinical pharmacy in mental health; European society of clinical pharmacy; Mental illnesses and pharmacy; Pharmaceutical services in mental health; Polypharmacy and clinical pharmacy; Psychotropics and clinical pharmacy
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 28. 2. 2024 07:22, Mgr. Daniela Černá
Anotace
V originále
A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.